|
1
|
Liam CK, Pang YK, Leow CH, et al: Changes
in the distribution of lung cancer cell types and patient
demography in a developing multiracial Asian country: Experience of
a university teaching hospital. Lung Cancer. 53:23–30. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
National Cancer Registry (2007). Malaysia
Cancer Statistics - Data and Figure, National Cancer Registry,
Malaysia. http://www.care.upm.edu.my/dokumen/13603_NCR2007.pdfAccessed.
September 08–2014
|
|
3
|
National Comprehensive Cancer Network:
2011 NCCN Clinical Practice Guidelines in Oncology: Non-small Cell
Lung Cancer, Version 1. National Comprehensive Cancer Network
(2011) NCCN Clinical Practice Guidelines in Oncology.
2011.http://www.nccn.org/patients/guidelines/nscl/index.htmlAccessed.
September 08–2014
|
|
4
|
Liam CK, Leow HR, How SH, Pang YK, Chua
KT, Lim BK, Lai NL, Kuan YC, Pailoor J and Rajadurai P: Epidermal
growth factor receptor mutations in non-small cell lung cancers in
a multiethnic malaysian patient population. Asian Pac J Cancer
Prev. 15:321–326. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Ho C, Murray N, Laskin J, Melosky B,
Anderson H and Bebb G: Asian ethnicity and adenocarcinoma histology
continues to predict response to gefitinib in patients treated for
advanced non-small cell carcinoma of the lung in North America.
Lung Cancer. 49:225–231. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Mok TS, Wu YL, Thongprasert S, Yang CH,
Chu DT, Saijo N, Sunpaweravong P, Han B, Margono B, Ichinose Y, et
al: Gefitinib or carboplatin-paclitaxel in pulmonary
adenocarcinoma. N Engl J Med. 361:947–957. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Mitsudomi T, Morita S, Yatabe Y, Negoro S,
Okamoto I, Tsurutani J, Seto T, Satouchi M, Tada H, Hirashima T, et
al: Gefitinib versus cisplatin plus docetaxel in patients with
non-small-cell lung cancer harbouring mutations of the epidermal
growth factor receptor (WJTOG3405): An open label, randomised phase
3 trial. Lancet Oncol. 11:121–128. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Maemondo M, Inoue A, Kobayashi K, Sugawara
S, Oizumi S, Isobe H, Gemma A, Harada M, Yoshizawa H, Kinoshita I,
et al: Gefitinib or chemotherapy for non-small-cell lung cancer
with mutated EGFR. N Engl J Med. 362:2380–2388. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Yang CH, Yu CJ, Shih JY, Chang YC, Hu FC,
Tsai MC, Chen KY, Lin ZZ, Huang CJ, Shun CT, et al: Specific EGFR
mutations predict treatment outcome of stage IIIB/IV patients with
chemotherapy-naive non-small-cell lung cancer receiving first-line
gefitinib monotherapy. J Clin Oncol. 26:2745–2753. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Chang A, Parikh P, Thongprasert S, Tan EH,
Perng RP, Ganzon D, Yang CH, Tsao CJ, Watkins C, Botwood N and
Thatcher N: Gefitinib (IRESSA) in patients of Asian origin with
refractory advanced non-small cell lung cancer: Subset analysis
from the ISEL study. J Thorac Oncol. 1:847–855. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Liam CK, Ruthranesan M, Lee CH, Pang YK,
Chua KT and Lim BK: Outcomes of Malaysian patients with advanced
lung adenocarcinoma and unknown epidermal growth factor receptor
mutation status treated with gefitinib. Asia Pac J Clin Oncol.
8:267–274. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Liam CK, Pang YK and Leow CH: Epidermal
growth factor receptor targeted therapy with gefitinib in locally
advanced and metastatic primary lung adenocarcinoma. Respirology.
11:287–291. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Fukuoka M, Yano S, Giaccone G, Tamura T,
Nakagawa K, Douillard JY, Nishiwaki Y, Vansteenkiste J, Kudoh S,
Rischin D, et al: Multi-institutional randomized phase II trial of
gefitinib for previously treated patients with advanced
non-small-cell lung cancer (The IDEAL 1 Trial) [corrected]. J Clin
Oncol. 21:2237–2246. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Kris MG, Natale RB, Herbst RS, Lynch TJ
Jr, Prager D, Belani CP, Schiller JH, Kelly K, Spiridonidis H,
Sandler A, et al: Efficacy of gefitinib, an inhibitor of the
epidermal growth factor receptor tyrosine kinase, in symptomatic
patients with non-small cell lung cancer: A randomized trial. JAMA.
290:2149–2158. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Thatcher N, Chang A, Parikh P, Pereira
Rodrigues J, Ciuleanu T, von Pawel J, Thongprasert S, Tan EH,
Pemberton K, Archer V and Carroll K: Gefitinib plus best supportive
care in previously treated patients with refractory advanced
non-small-cell lung cancer: Results from a randomised,
placebo-controlled, multicentre study (Iressa Survival Evaluation
in Lung Cancer). Lancet. 366:1527–1537. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Lynch TJ, Bell DW, Sordella R,
Gurubhagavatula S, Okimoto RA, Brannigan BW, Harris PL, Haserlat
SM, Supko JG, Haluska FG, et al: Activating mutations in the
epidermal growth factor receptor underlying responsiveness of
non-small-cell lung cancer to gefitinib. N Engl J Med.
350:2129–2139. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Morita S, Okamoto I, Kobayashi K, Yamazaki
K, Asahina H, Inoue A, Hagiwara K, Sunaga N, Yanagitani N, Hida T,
et al: Combined survival analysis of prospective clinical trials of
gefitinib for non-small cell lung cancer with EGFR mutations. Clin
Cancer Res. 15:4493–4498. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Kim ES, Hirsh V, Mok T, Socinski MA,
Gervais R, Wu YL, Li LY, Watkins CL, Sellers MV, Lowe ES, et al:
Gefitinib versus docetaxel in previously treated non-small-cell
lung cancer (INTEREST): A randomised phase III trial. Lancet.
372:1809–1818. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Miller VA, Kris MG, Shah N, Patel J,
Azzoli C, Gomez J, Krug LM, Pao W, Rizvi N, Pizzo B, et al:
Bronchioloalveolar pathologic subtype and smoking history predict
sensitivity to gefitinib in advanced non-small-cell lung cancer. J
Clin Oncol. 22:1103–1109. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Iuchi T, Shingyoji M, Sakaida T, Hatano K,
Nagano O, Itakura M, Kageyama H, Yokoi S, Hasegawa Y, Kawasaki K
and Iizasa T: Phase II trial of gefitinib alone without radiation
therapy for Japanese patients with brain metastases from
EGFR-mutant lung adenocarcinoma. Lung Cancer. 82:282–287. 2013.
View Article : Google Scholar : PubMed/NCBI
|
